Goal: to enable the rapid assessment of the biological impacts of new variants of SARS-CoV-2.
|
Scientific reports | Previous Versions: CURRENT REPORT | 30 Aug 2022 | 8 July 2022 | 27 May 2022| 25 Mar 2022 | 25 Feb 2022 |19 Jan 2022 | 20 Dec 2021 | 22 Nov 2021 | 08 Nov 2021 | 25 Oct 2021 | 8 Oct 2021 | 7 Sep 2021 | 23 Aug 2021 | 02 Aug 2021 | 12 Jul 2021 Contact: Questions? Contact us at agility@cepi.net |
Aims of the Agility project:
- Rapid identification of new variants of SARS-CoV-2 that may impact COVID-19 vaccines and countermeasures
- Comparative neutralisation testing of identified variants of concern using a panel of sera and WHO International antibody standard
- Assessment of pathogenesis of variants of concern in relevant SARS-CoV-2 animal models
- Timely reports and information sharing on the biological activity (antigenic characteristics and pathogenesis in animals) of emerging variants
- Predictability and comparability achieved through standard procedures and parallel testing in 2 independent laboratories